Vanguard Group’s Cardio Diagnostics CDIO Stock Holding History

Vanguard Group’s Portfolio CDIO Stock Details CDIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$65.4K	Hold	24,124	–	–	﹤0.01%	4213
2025 Q3	$97.2K	Buy	24,124 +11,442	+90%	+$45.2K	﹤0.01%	4230
2025 Q2	$45.7K	Buy	12,682 +265	+2%	+$1.98K	﹤0.01%	4204
2025 Q1	$123K	Buy	12,417 +4,679	+60%	+$72.9K	﹤0.01%	4114
2024 Q4	$213K	Hold	7,738	–	–	﹤0.01%	4096
2024 Q3	$51.8K	Hold	7,738	–	–	﹤0.01%	4244
2024 Q2	$128K	Hold	7,738	–	–	﹤0.01%	4208
2024 Q1	$330K	Hold	7,738	–	–	﹤0.01%	4096
2023 Q4	$578K	Buy	7,738 +5,604	+263%	+$194K	﹤0.01%	3988
2023 Q3	$21.8K	Hold	2,134	–	–	﹤0.01%	4490
2023 Q2	$76.2K	Hold	2,134	–	–	﹤0.01%	4412
2023 Q1	$250K	Buy	+2,134	New	+$168K	﹤0.01%	4285

Other funds holding CDIO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Vanguard Group's CDIO Position: Q4 2025 in Review

Vanguard Group held its Cardio Diagnostics (CDIO) position steady in Q4 2025 at 24,124 shares worth $65.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4213.

Vanguard Group first reported a position in CDIO in Q1 2023 and has held it in 12 quarters since. The position peaked at $578K in Q4 2023. 16 funds tracked by Wall St. Rank hold CDIO as of Q4 2025.

Vanguard Group held 24,124 shares of Cardio Diagnostics worth $65.4K as of Q4 2025.
Vanguard Group left its Cardio Diagnostics share count unchanged in Q4 2025.
Cardio Diagnostics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4213 holding.
Vanguard Group first reported a position in Cardio Diagnostics in Q1 2023 and has held it in 12 quarters since.
Vanguard Group's Cardio Diagnostics position peaked at $578K in Q4 2023.
16 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.